QTTB Q32 Bio Inc.
Price (delayed)
$1.485
Market cap
$18.11M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.12
Enterprise value
-$42.21M
homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
Highlights
Q32 Bio's gross profit has surged by 100% QoQ and by 100% YoY
Q32 Bio's revenue has soared by 100% from the previous quarter and by 100% YoY
QTTB's quick ratio has surged by 115% year-on-year but it is down by 24% since the previous quarter
QTTB's equity has soared by 103% year-on-year but it has dropped by 69% since the previous quarter
Key stats
What are the main financial stats of QTTB
Market
Valuations
Earnings
Shares outstanding
12.2M
Market cap
$18.11M
Enterprise value
-$42.21M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.19
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$66.1M
Net income
-$47.73M
EBIT
-$47.71M
EBITDA
-$46.65M
Free cash flow
-$67.79M
Per share
Balance sheet
Liquidity
EPS
-$5.12
EPS diluted
-$6.58
Free cash flow per share
-$7.27
Book value per share
$0.47
Revenue per share
$0
TBVPS
$9.91
Total assets
$92.33M
Total liabilities
$86.66M
Debt
$18.29M
Equity
$5.68M
Working capital
$65.41M
Debt to equity
3.22
Current ratio
4.97
Quick ratio
4.77
Net debt/EBITDA
1.29
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-40.3%
Return on equity
-179.7%
Return on invested capital
-228.9%
Return on capital employed
-62.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
QTTB stock price
How has the Q32 Bio stock price performed over time
Intraday
-1%
1 week
-25.38%
1 month
-34.58%
1 year
-93.24%
YTD
-56.83%
QTD
-10%
Financial performance
How have Q32 Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$66.1M
Net income
-$47.73M
Gross margin
N/A
Net margin
N/A
Q32 Bio's gross profit has surged by 100% QoQ and by 100% YoY
Q32 Bio's revenue has soared by 100% from the previous quarter and by 100% YoY
The operating income has declined by 37% year-on-year but it is up by 15% since the previous quarter
QTTB's net income is up by 21% since the previous quarter and by 11% year-on-year
Growth
What is Q32 Bio's growth rate over time
Valuation
What is Q32 Bio stock price valuation
P/E
N/A
P/B
3.19
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
QTTB's EPS has soared by 97% YoY and by 94% from the previous quarter
QTTB's equity has soared by 103% year-on-year but it has dropped by 69% since the previous quarter
The P/B is 71% below the last 4 quarters average of 11.1 and 11% below the 5-year quarterly average of 3.6
Q32 Bio's revenue has soared by 100% from the previous quarter and by 100% YoY
Efficiency
How efficient is Q32 Bio business performance
The return on equity has declined by 48% year-on-year
The ROA has grown by 29% from the previous quarter but it has contracted by 3.9% YoY
Q32 Bio's return on invested capital has decreased by 14% QoQ
Dividends
What is QTTB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for QTTB.
Financial health
How did Q32 Bio financials performed over time
The total assets is 7% greater than the total liabilities
The current ratio has surged by 144% year-on-year but it has declined by 24% since the previous quarter
QTTB's quick ratio has surged by 115% year-on-year but it is down by 24% since the previous quarter
QTTB's equity has soared by 103% year-on-year but it has dropped by 69% since the previous quarter
QTTB's debt has dropped by 64% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.